Nexalin Technology, Inc. Common Stock represents an equity interest in Nexalin Technology, Inc., a medical device company focused on neurostimulation products for mental health and related neurological conditions. The company develops noninvasive bioelectronic systems designed to deliver targeted stimulation through headset-based and forehead-mounted devices, with applications in areas such as anxiety, insomnia, depression, substance use disorder, traumatic brain injury, post-traumatic stress disorder, chronic pain, and other brain-health conditions. Nexalin Technology serves clinicians and patients through products intended for use in medical settings and, in some cases, at home under professional guidance. Its product portfolio is centered on neuromodulation therapies that aim to provide drug-free treatment options within the healthcare and medical technology markets. The stock is used by investors to track ownership in a specialized healthcare company operating at the intersection of medical devices, digital health, and neurotechnology.
Website1776 Yorktown
Houston, TX, 77056
United States
What share of all stock conversation is about NXL?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0% 0 | 0% new | 0% 0 | 0% -0.01 |
Of the messages about NXL that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | — | — | 100% +38.46 | 86.37% -11.49 | ||
| Bearish | — | — | 0% -38.46 | 13.63% +11.49 |
Of the messages about NXL that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Announcements | — | — | 25% | 41.55% | ||
| Technical Analysis | — | — | 75% | 27.57% | ||
| Analysts | — | — | 0% | 11.27% | ||
| Controversies | — | — | 0% | 3.42% | ||
| Earnings | — | — | 0% | 0% | ||
| Macro | — | — | 0% | 16.2% |
Of the messages about NXL, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | — | 100% | 62.5% | 32.65% | ||
| Newcomers | — | 0% | 37.5% | 67.35% |
ORLANDO, FL / ACCESS Newswire / September 11, 2026 / RedChip Companies will air interviews with Anixa Biosciences Inc. (NASDAQ:ANIX) and Nexalin Technology Inc.
Further analysis of ADAS-Cog data from the Company’s randomized, sham-controlled clinical trial — previously published in the Journal of Alzheimer’s Disease and in Radiology — identifies specific improvements in cognitive domains associated with memory in Alzheimer’s patients One half of evaluable active-arm participants achieved a clinically meaningful improvement of four or more points on the ADAS-Cog, with domain-level gains in comprehension, memory and language function still evident three m
Detailed price information for Nexalin Technology Inc (NXL-Q) from The Globe and Mail including charting and trades.
Investors talking about NXL also mention